Pharmacist-Led Deprescribing to Prevent Medication Burden

Abstract

Pharmacist-led deprescribing initiatives have emerged as a pivotal intervention in mitigating medication burden, particularly among the elderly and patients with multimorbidity. This review explores the epidemiology of polypharmacy, outlines the pathophysiological consequences of inappropriate medication use, and discusses risk factors and clinical features associated with medication burden. It synthesizes current diagnostic strategies, evaluates evidence-based management frameworks, and examines emerging deprescribing approaches. Guideline recommendations and practical implications for healthcare professionals are highlighted, with emphasis on multidisciplinary collaboration and patient-centered care.

Introduction

The growing complexity of pharmacotherapy, particularly in aging populations, has led to a significant increase in medication burden and polypharmacy. Polypharmacy, defined as the use of five or more medications, is closely linked to adverse drug reactions (ADRs), drug-drug interactions, decreased adherence, and increased healthcare utilization. Pharmacist-led deprescribing, a systematic process of identifying and discontinuing unnecessary or potentially harmful medications, has gained prominence as a strategy to enhance medication safety and optimize therapeutic outcomes. The integration of pharmacists in multidisciplinary healthcare teams positions them uniquely to assess pharmacotherapy regimens, identify prescribing cascades, and implement evidence-based deprescribing protocols. This article presents a comprehensive review of pharmacist-led deprescribing, encompassing epidemiological trends, mechanistic underpinnings, risk stratification, clinical presentation, assessment methods, and evolving therapeutic strategies.

Epidemiology / Disease Burden

Polypharmacy prevalence is rising globally, with studies indicating that up to 40% of older adults in developed nations are prescribed five or more medications. The burden is especially high in long-term care facilities, where complex comorbidities necessitate multiple drug therapies. Polypharmacy is strongly associated with adverse outcomes, including an increased risk of falls, cognitive impairment, hospitalizations, and mortality. The economic burden is substantial, with medication-related problems accounting for significant portions of healthcare expenditures. Notably, inappropriate prescribing, including the use of potentially inappropriate medications (PIMs) as defined by Beers Criteria and STOPP/START criteria, remains common and is a modifiable contributor to medication burden.

Pathophysiology

The pathophysiological consequences of medication burden stem from pharmacokinetic and pharmacodynamic changes, particularly in older adults. Age-related alterations in renal and hepatic function, body composition, and receptor sensitivity increase susceptibility to ADRs and cumulative toxicity. Polypharmacy elevates the risk of drug-drug interactions, leading to unpredictable therapeutic and adverse effects. Inappropriate medication continuation can result in prescribing cascades, where new drugs are added to manage side effects of existing therapies, further exacerbating polypharmacy. Chronic exposure to certain drug classes, such as anticholinergics and benzodiazepines, is linked to cognitive decline and functional impairment, highlighting the need for proactive deprescribing interventions.

Risk Factors

Risk factors for medication burden include advanced age, multimorbidity, transitions of care (e.g., hospital discharge), fragmented healthcare delivery, and lack of coordinated medication review. Patients with cognitive impairment, limited health literacy, or residing in institutional settings are at heightened risk. Prescriber-related factors, such as therapeutic inertia, inadequate communication, and insufficient awareness of deprescribing principles, further contribute to the persistence of unnecessary medications. Socioeconomic disparities and polypharmacy-promoting healthcare policies also play a role in perpetuating medication burden across populations.

Clinical Features

Clinical manifestations of medication burden are often subtle and nonspecific, ranging from mild cognitive changes and fatigue to severe events such as delirium, syncope, and falls. Polypharmacy increases the risk of adverse drug reactions, which can mimic or exacerbate underlying comorbidities. Inappropriate medication use may also contribute to functional decline, reduced quality of life, and increased healthcare resource utilization. Recognition of these features is essential for timely identification and intervention.

Diagnosis

Diagnosis of medication burden involves comprehensive medication reconciliation and review, utilizing structured tools such as the Medication Appropriateness Index, Beers Criteria, and STOPP/START criteria. Clinical pharmacists employ these tools to systematically assess each medication for indication, effectiveness, safety, and adherence. Patient interviews, review of medical records, and interprofessional collaboration are integral to identifying unnecessary or harmful medications. Risk stratification models, such as the Medication Regimen Complexity Index (MRCI), aid in quantifying burden and prioritizing deprescribing interventions.

Treatment & Management

Effective management of medication burden centers on pharmacist-led deprescribing practices, characterized by individualized risk-benefit assessment, shared decision-making, and patient engagement. The deprescribing process includes identifying target medications, evaluating ongoing need, monitoring for withdrawal or symptom recurrence, and providing education to patients and caregivers. Multidisciplinary collaboration among pharmacists, physicians, nurses, and other healthcare providers is critical to ensure safe and effective implementation. Pharmacists leverage their pharmacotherapeutic expertise to recommend alternative therapies, adjust dosing, and monitor for clinical outcomes. Regular medication reviews, especially during care transitions, are essential to sustaining deprescribing efforts and preventing re-initiation of unnecessary therapies.

Recent Advances / Emerging Therapies

Recent advances in deprescribing include the development of electronic decision support tools, integration of deprescribing algorithms into electronic health records, and the use of artificial intelligence to flag high-risk medication regimens. Randomized controlled trials, such as the D-PRESCRIBE and OPTIMIZE studies, have demonstrated that pharmacist-led interventions significantly reduce inappropriate medication use, adverse events, and healthcare utilization. Emerging research also highlights the role of telepharmacy and remote consultations in expanding access to deprescribing services, particularly in rural or underserved settings. Ongoing studies are evaluating the impact of deprescribing on patient-centered outcomes, including quality of life, functional status, and healthcare costs.

Guideline Recommendations

Current clinical guidelines, including those from the American Geriatrics Society and the National Institute for Health and Care Excellence (NICE), advocate for routine medication review and deprescribing in older adults and high-risk populations. Recommendations emphasize the importance of individualized assessment, use of validated screening tools, and shared decision-making. Guidelines underscore the central role of pharmacists in leading deprescribing initiatives, providing education, and fostering interprofessional communication. Regular reassessment and documentation of deprescribing interventions are recommended to ensure ongoing safety and effectiveness.

Conclusion

Pharmacist-led deprescribing is a vital, evidence-based strategy to reduce medication burden and improve patient outcomes. By leveraging their pharmacological expertise and collaborative approach, pharmacists are uniquely positioned to identify inappropriate medications, implement tailored deprescribing protocols, and support safe medication use. Integration of deprescribing into routine clinical practice, guided by contemporary guidelines and supported by emerging technologies, holds promise for optimizing pharmacotherapy, enhancing patient safety, and reducing healthcare costs. Continued research and multidisciplinary engagement are essential to advance the science and practice of deprescribing in diverse clinical settings.